Congestive heart failure market across 7MM to rise 8% CAGR through 2036

Growth is fuelled by rising disease burden, ageing populations, and earlier diagnosis.

The global congestive heart failure (CHF) treatment market across the seven major markets (7MM) was valued at $9b in 2025 and is projected to rise at a compound annual growth rate (CAGR) of 8% between 2026 and 2036, according to DelveInsight Business Research.

Growth is expected to be driven by the increasing prevalence of cardiovascular diseases, a growing ageing population, and greater emphasis on early diagnosis and disease management.

The market is also expected to benefit from the potential introduction of new therapies, including omecamtiv mecarbil (Cytokinetics), ziltivekimab (NN6018; Novo Nordisk), CardiALLO Cell Therapy (BioCardia), and umiposgene parvec (Bayer).

The US represented the largest share of the CHF treatment market amongst the 7MM in 2025, ahead of other major markets such as Germany, France, Italy, Spain, the United Kingdom, and Japan.

The 7MM had an estimated 21.1 million diagnosed prevalent heart failure cases in 2025.

Several companies are developing new CHF therapies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, and AskBio.

Key investigational treatments include omecamtiv mecarbil, ziltivekimab, CardiALLO Cell Therapy, CardiAMP Cell Therapy, CRD-740, umiposgene parvec, AZD5462, vicadrostat (BI 690517) combined with empagliflozin, rexlemestrocel-L, and AB-1002 gene therapy.

Future market growth is expected to be shaped by continued research into new therapeutic approaches, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and regenerative cell therapies.